Table 1.
Clinical characteristics in total patients.
| n = 257 | |
|---|---|
| Age, years | 55 (37–72) |
| > 65 years old, n | 84 (32.7%) |
| Sex | |
| Male | 146 (56.8%) |
| Female | 111 (43.2%) |
| BMI, kg/m2 | 23.1 (20.4–25.8) |
| Time from onset to admission, days | 5 (3–8) |
| Disease severity†, n | |
| Mild to moderate I | 182 (70.8%) |
| Moderate II to severe | 75 (29.2%) |
| Treatment regimen, n | |
| Systemic corticosteroids | 63 (24.5%) |
| Remdesivir | 38 (14.8%) |
| Favipiravir | 49 (19.1%) |
| Tocilizumab | 5 (1.9%) |
| Comorbidities, n | |
| Hypertension | 77 (30.0%) |
| Diabetes mellitus | 27 (10.5%) |
| Dyslipidemia | 46 (17.9%) |
| Hyperuricemia | 9 (3.5%) |
| Asthma | 22 (8.6%) |
| COPD | 13 (5.1%) |
| Chronic heart failure | 33 (12.8%) |
| Immunodeficiency | 14 (5.4%) |
The data are presented as median (range) or number (percentage). BMI body mass index, COPD chronic obstructive pulmonary disease.
†Disease severity was based on the classification developed by the Japanese Ministry of Health, Labor and Welfare.